



Hangwen Li, got his medical degree from China and Ph .D. from University of Texas at Austin and University of Texas MD Anderson Cancer Center, Postdoctoral training from Houston Methodist Hospital and University of Michigan Medical School, After founded the Stemirna Therapeutics in Shanghai, Hangmen has served as the Chairman of the Board of Stemirna Therapeutics since its inception and assumed the role of CEO in middle of 2016. Stemirna uses its novel LPP/mRNA delivery platform which has an unique core-shell structure and mainly composed of liposomes and a unique polymer. Stemirna intends to be the first mRNA based drug and vaccine company in China to provide safety, stability, and efficacy mRNA cancer vaccines.